Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Transmucosal oxygen tension of the clitoris: a new parameter for future investigations of the sexual, metabolic, and cardiovascular health of women.

Endocrine·2018

Same author

Integrated cardiovascular/respiratory control in type 1 diabetes evidences functional imbalance: Possible role of hypoxia.

International journal of cardiology·2017

Same author

Association between low C-peptide and fragility fractures in postmenopausal women without diabetes.

Journal of endocrinological investigation·2017

Same author

Association between low C-peptide and low lumbar bone mineral density in postmenopausal women without diabetes.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015

Same author

Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor?

Acta diabetologica·2014

Same author

Concomitant carotid plaque development and brachial artery diameter enlargement: a retrospective, recall-based study in postmenopausal women.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2012

Same journal

[Prevention in coronary postangioplasty restenosis with omega-3 fatty acids. Results of the Italian study on prevention of restenosis with esapent (ESPRIT)].

Cardiologia (Rome, Italy)·2002

Same journal

[Results of GISSI Prevenzione: diet, drugs, and cardiovascular risk. Researchers of GISSI Prevenzione].

Cardiologia (Rome, Italy)·2002

Same journal

[New therapeutic strategies in heart failure. Which patients need defibrillation backup?].

Cardiologia (Rome, Italy)·2002

Same journal

[Electromechanical re-synchronization with sequential heart stimulation as a new non-pharmacologic treatment of advanced heart failure. Physiopathologic features and clinical results].

Cardiologia (Rome, Italy)·2002

Same journal

[New therapeutic strategies in heart failure. Pharmacologic therapy].

Cardiologia (Rome, Italy)·2002

Same journal

[Genetics as a guide for antihypertensive therapy: future perspectives].

Cardiologia (Rome, Italy)·2002

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Quantification of Atherosclerosis in Mice

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Genetics and cardiovascular risk: a role for apolipoprotein(a) polymorphism.

C Gazzaruso¹, A Garzaniti, D Geroldi

¹Dipartimento di Medicina Interna e Terapia Medica, IRCCS Policlinico San Matteo, Università degli Studi, Pavia.

Cardiologia (Rome, Italy)

|June 18, 1999

Summary

This summary is machine-generated.

Apolipoprotein(a) [apo(a)] isoforms, beyond lipoprotein(a) [Lp(a)] levels, predict cardiovascular disease risk. Apo(a) phenotyping aids in assessing atherothrombosis risk, especially in high-risk patients.

More Related Videos

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jun 24, 2026

Quantification of Atherosclerosis in Mice

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

Area of Science:

Cardiovascular Genetics
Atherothrombosis Research
Clinical Biochemistry

Background:

Lipoprotein(a) [Lp(a)] is a known cardiovascular risk factor, with apolipoprotein(a) [apo(a)] as its specific protein component.
Apo(a) exhibits significant genetic polymorphism, with over 34 identified plasma isoforms.
Emerging evidence suggests apo(a) polymorphism may influence atherothrombosis independently of Lp(a) levels.

Purpose of the Study:

To investigate the independent role of apo(a) polymorphism in cardiovascular disease.
To evaluate the clinical utility of apo(a) phenotyping in predicting atherothrombosis.
To explore the association between apo(a) phenotypes and coronary heart disease severity and onset.

Main Methods:

High-resolution phenotyping methods for detecting apo(a) isoforms.
Analysis of apo(a) polymorphism in various patient cohorts, including those with hypertension, diabetes, and uremia.
Correlation of apo(a) phenotypes with coronary atherosclerosis severity and age of disease onset.

Main Results:

Apo(a) phenotypes show strong predictive value for coronary heart disease, particularly when detected by high-resolution methods and using adequate cut-offs.
Significant associations between apo(a) phenotypes and coronary heart disease were observed in hypertensive, diabetic, and uremic patients.
Apo(a) phenotypes correlate with the severity of coronary atherosclerosis and the age of clinical onset of coronary heart disease.

Conclusions:

Apo(a) polymorphism offers significant clinical utility in primary prevention strategies for cardiovascular disease.
Apo(a) phenotypes, alongside Lp(a) levels, serve as potent genetic predictors of atherothrombosis.
Apo(a) polymorphism analysis is particularly valuable in healthy individuals with a family history of atherothrombosis, high-risk patients, and those with conditions affecting Lp(a) levels.